v3.22.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Net sales
Cost of sales
Gross profit
Operating expenses:        
Research and development, net of grants 843 695 1,488 1,029
Clinical and regulatory, net of grants 161 263 266 300
General and administrative 2,125 1,338 3,591 3,810
Total operating expenses 3,129 2,296 5,345 5,139
Loss from operations (3,129) (2,296) (5,345) (5,139)
Other income (expense), net 53 2 57 2
Net loss $ (3,076) $ (2,294) $ (5,288) $ (5,137)
Net loss per common share – basic and diluted $ (0.08) $ (0.08) $ (0.13) $ (0.20)
Weighted average common shares outstanding – basic and diluted 39,409 28,667 39,409 26,117

Source